Veloxis Pharmaceuticals A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Veloxis Pharmaceuticals A/S
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at some of the most significant regional pharma stories of the past few weeks.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- H. Lundbeck A/S, LifeCycle Pharma A/S